InveniAI® LLC, a company involved in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to transform innovation across drug discovery and development, has announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd. a global, research-driven pharmaceutical company.
The multi-year collaboration will combine InveniAI's AI platform, AlphaMeld®, to research and validate targets with Shionogi's expertise in developing and commercializing appropriate therapeutic modalities. Shionogi will synthesize drugs against targets proposed by InveniAI for certain strategic diseases of interest to Shionogi and be responsible for developing, manufacturing, and commercializing the candidates.
"Shionogi constantly strives to supply the best possible medicines to protect the health and wellbeing of the patients we serve, and we are delighted to further this mission through our collaboration with InveniAI. This collaboration allows us to use the power of AI to automate the early discovery phase by trawling vast datasets to identify targets, find candidate molecules, and predict favorable outcomes. This will ultimately help us reduce discovery times and get our medicines to patients who are living without favorable treatment options," said Ryuichi Kiyama, Ph.D., Executive Vice President, Senior Executive Officer, Head of Pharmaceutical Research Division.
"As we increasingly witness the transformational impact of AI applications in pharmaceutical development, we are excited to combine forces with Shionogi to apply an efficient data-driven approach to drug discovery. Our AI platform, AlphaMeld®, can comprehensively identify biological targets for a disease and align the best drug modalities while prioritizing both safety and efficacy. The complex balance of scientific, medical, chemical, biological, and strategic considerations is taken into account so that our domain experts and drug developers can quickly get to work knowing that all the crucial data points have been considered in searching for transformational treatment options," said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI. "The platform has seen multiple validations through our collaborations and is now well-positioned for de-novo drug discovery," he added.
InveniAI® is eligible to receive up to $200 million per program for a combination of upfront payments, development and commercial milestones, and royalties.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!